Miyajima Akira, Kikuchi Eiji, Kosaka Takeo, Oya Mototsugu
Keio University School of Medicine, Department of Urology, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Rev Recent Clin Trials. 2009 May;4(2):75-8. doi: 10.2174/157488709788185996.
The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.
基于血管紧张素II（AII）已知的激素作用及其血管收缩作用，人们怀疑它具有促进肿瘤生长的可能性。有人提出，血管紧张素转换酶（ACE）抑制剂可能对癌症具有保护作用，并可能预防癌症发生。多项研究报告称，AII可通过1型AII受体（AT1R）在实验系统中诱导新血管形成。AT1R在皮肤癌、肾细胞癌和乳腺癌等人类肿瘤中也经常表达。最近越来越多专注于用AT1R拮抗剂进行治疗的研究表明，血管紧张素受体阻断（ARB）似乎不仅能抑制癌细胞的生长，还能抑制肿瘤血管生成。我们在此描述AT1R阻断的作用，这些作用表明肿瘤血管生成与泌尿生殖系统癌症有关，因为ARB可能是一种抗癌治疗的替代方式。
